Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

MicroRNA-188-5p inhibits hepatocellular carcinoma proliferation and migration by targeting forkhead box N2

Authors: Yan-hui Wu, Bin Yu, Jiang-min Zhou, Xue-han Shen, Wei-xun Chen, Xi Ai, Chao Leng, Bin-yong Liang, Ya-jie Shao

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

This study aimed to identify the biological functions, expression modes, and possible mechanisms underlying the relationship between metastatic human hepatocellular carcinoma (HCC) and MicroRNA-188-5p (miR-188) dysregulation using cell lines.

Methods

A decrease in miR-188 was detected in low and high metastatic HCC cells compared to that in normal hepatic cells and non-invasive cell lines. Gain- and loss-of-function experiments were performed in vitro to investigate the role of miR-188 in cancer cell (Hep3B, HepG2, HLF, and LM3) proliferation and migration.

Results

miR-188 mimic transfection inhibited the proliferation of metastatic HLF and LM3 cells but not non-invasive HepG2 and Hep3B cells; nonetheless, miR-188 suppression promoted the growth of HLF and LM3 cells. miR-188 upregulation inhibited the migratory rate and invasive capacity of HLF and LM3, rather than HepG2 and Hep3B cells, whereas transfection of a miR-188 inhibitor in HLF and LM3 cells had the opposite effects. Dual-luciferase reporter assays and bioinformatics prediction confirmed that miR-188 could directly target forkhead box N2 (FOXN2) in HLF and LM3 cells. Transfection of miR-188 mimics reduced FOXN2 levels, whereas miR-188 inhibition resulted in the opposite result, in HLF and LM3 cells. Overexpression of FOXN2 in HLF and LM3 cells abrogated miR-188 mimic-induced downregulation of proliferation, migration, and invasion. In addition, we found that miR-188 upregulation impaired tumor growth in vivo.

Conclusions

In summary, this study showed thatmiR-188 inhibits the proliferation and migration of metastatic HCC cells by targeting FOXN2.
Appendix
Available only for authorised users
Literature
2.
go back to reference Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut. 2018;67:2006–16.CrossRefPubMed Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut. 2018;67:2006–16.CrossRefPubMed
3.
go back to reference Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152:1954–64.CrossRefPubMed Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152:1954–64.CrossRefPubMed
4.
go back to reference Weidle UH, Schmid D, Birzele F, Brinkmann U. MicroRNAs involved in metastasis of hepatocellular carcinoma: target candidates, functionality and efficacy in animal models and prognostic relevance. Cancer Genomics Proteomics. 2020;17:1–21.CrossRefPubMedPubMedCentral Weidle UH, Schmid D, Birzele F, Brinkmann U. MicroRNAs involved in metastasis of hepatocellular carcinoma: target candidates, functionality and efficacy in animal models and prognostic relevance. Cancer Genomics Proteomics. 2020;17:1–21.CrossRefPubMedPubMedCentral
6.
go back to reference Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12:2189–204.CrossRefPubMedPubMedCentral Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12:2189–204.CrossRefPubMedPubMedCentral
7.
go back to reference Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci Rep. 2019;9:10464.CrossRefPubMedPubMedCentral Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci Rep. 2019;9:10464.CrossRefPubMedPubMedCentral
8.
go back to reference Zhu X, Qiu J, Zhang T, Yang Y, Guo S, Li T, et al. MicroRNA-188-5p promotes apoptosis and inhibits cell proliferation of breast cancer cells via the MAPK signaling pathway by targeting Rap2c. J Cell Physiol. 2020;235:2389–402.CrossRefPubMed Zhu X, Qiu J, Zhang T, Yang Y, Guo S, Li T, et al. MicroRNA-188-5p promotes apoptosis and inhibits cell proliferation of breast cancer cells via the MAPK signaling pathway by targeting Rap2c. J Cell Physiol. 2020;235:2389–402.CrossRefPubMed
9.
go back to reference Fang F, Chang RM, Yu L, Lei X, Xiao S, Yang H, et al. MicroRNA-188–5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 2015;63:874–85.CrossRefPubMed Fang F, Chang RM, Yu L, Lei X, Xiao S, Yang H, et al. MicroRNA-188–5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 2015;63:874–85.CrossRefPubMed
10.
go back to reference Cheng N, Wu J, Yin M, Xu J, Wang Y, Chen X, et al. LncRNA CASC11 promotes cancer cell proliferation in hepatocellular carcinoma by inhibiting miRNA-188-5p. Biosci Rep. 2019;39:BSR20190251.CrossRefPubMedPubMedCentral Cheng N, Wu J, Yin M, Xu J, Wang Y, Chen X, et al. LncRNA CASC11 promotes cancer cell proliferation in hepatocellular carcinoma by inhibiting miRNA-188-5p. Biosci Rep. 2019;39:BSR20190251.CrossRefPubMedPubMedCentral
11.
go back to reference Ma J, Qin C, Yuan Z, Liu S. LncRNA PAPAS promotes hepatocellular carcinoma by interacting with miR-188-5p. J Cell Biochem. 2019;120:13494–500.CrossRefPubMed Ma J, Qin C, Yuan Z, Liu S. LncRNA PAPAS promotes hepatocellular carcinoma by interacting with miR-188-5p. J Cell Biochem. 2019;120:13494–500.CrossRefPubMed
14.
go back to reference Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.CrossRefPubMedPubMedCentral Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.CrossRefPubMedPubMedCentral
15.
go back to reference Jinlong S, Lin F, Yonghui L, Li Y, Weidong W. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. PLoS One. 2015;10:e0118099.CrossRefPubMedPubMedCentral Jinlong S, Lin F, Yonghui L, Li Y, Weidong W. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. PLoS One. 2015;10:e0118099.CrossRefPubMedPubMedCentral
16.
go back to reference Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo J, et al. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget. 2015;6:6092.CrossRefPubMedPubMedCentral Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo J, et al. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget. 2015;6:6092.CrossRefPubMedPubMedCentral
17.
go back to reference Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013;328:198–206.CrossRefPubMed Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013;328:198–206.CrossRefPubMed
18.
go back to reference Tribioli C, Robledo RF, Lufkin T. The murine fork head gene Foxn2 is expressed in craniofacial, limb, CNS and somitic tissues during embryogenesis. Mech Dev. 2002;118:161–3.CrossRefPubMed Tribioli C, Robledo RF, Lufkin T. The murine fork head gene Foxn2 is expressed in craniofacial, limb, CNS and somitic tissues during embryogenesis. Mech Dev. 2002;118:161–3.CrossRefPubMed
19.
go back to reference Ye H, Duan M. FOXN2 is downregulated in breast cancer and regulates migration, invasion, and epithelial–mesenchymal transition through regulation of SLUG. Cancer Manag Res. 2019;11:525.CrossRefPubMedPubMedCentral Ye H, Duan M. FOXN2 is downregulated in breast cancer and regulates migration, invasion, and epithelial–mesenchymal transition through regulation of SLUG. Cancer Manag Res. 2019;11:525.CrossRefPubMedPubMedCentral
20.
go back to reference Ma J, Lu Y, Zhang S, Li Y, Huang J, Yin Z, et al. β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer. Cell Death Differ. 2018;25:1473–85.CrossRefPubMedPubMedCentral Ma J, Lu Y, Zhang S, Li Y, Huang J, Yin Z, et al. β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer. Cell Death Differ. 2018;25:1473–85.CrossRefPubMedPubMedCentral
21.
go back to reference Dai S, Guo L, Xia X, Pan Y. Long non-coding RNA WT1-AS inhibits cell aggressiveness via miR-203a-5p/FOXN2 axis and is associated with prognosis in cervical cancer. Eur Rev Med Pharmacol Sci. 2019;23:486–95.PubMed Dai S, Guo L, Xia X, Pan Y. Long non-coding RNA WT1-AS inhibits cell aggressiveness via miR-203a-5p/FOXN2 axis and is associated with prognosis in cervical cancer. Eur Rev Med Pharmacol Sci. 2019;23:486–95.PubMed
22.
go back to reference Liu X, Liu L, Xu X, Hua M, Kang Q, Li A, et al. FOXN2 suppresses the proliferation and invasion of human hepatocellular carcinoma cells. Eur Rev Med Pharmacol Sci. 2021;25:731–7.PubMed Liu X, Liu L, Xu X, Hua M, Kang Q, Li A, et al. FOXN2 suppresses the proliferation and invasion of human hepatocellular carcinoma cells. Eur Rev Med Pharmacol Sci. 2021;25:731–7.PubMed
Metadata
Title
MicroRNA-188-5p inhibits hepatocellular carcinoma proliferation and migration by targeting forkhead box N2
Authors
Yan-hui Wu
Bin Yu
Jiang-min Zhou
Xue-han Shen
Wei-xun Chen
Xi Ai
Chao Leng
Bin-yong Liang
Ya-jie Shao
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10901-7

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine